Bio-Rad Laboratories (BIO) 10-Q 27 Oct 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Oct. 20, 2023
Document Transition Report	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
City Area Code	(510)
Document Quarterly Report	true
Entity Incorporation, State or Country Code	DE
Entity File Number	1-7928
Entity Registrant Name	BIO-RAD LABORATORIES, INC.
Entity Central Index Key	0000012208
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Small Business	false
Entity Tax Identification Number	94-1381833
Entity Address, Address Line One	1000 Alfred Nobel Drive,
Entity Address, City or Town	Hercules,
Entity Address, Country	CA
Entity Address, Postal Zip Code	94547
Local Phone Number	724-7000
Entity Emerging Growth Company	false
Common Class A [Member]
Title of 12(b) Security	Class A Common Stock, Par Value $0.0001 per share
Trading Symbol	BIO
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		24,059,355
Common Class B [Member]
Title of 12(b) Security	Class B Common Stock, Par Value $0.0001 per share
Trading Symbol	BIOb
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		5,085,815

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
ASSETS:
Cash and cash equivalents	$ 457,850	$ 434,215
Short-term investments	1,301,143	1,356,457
Restricted investments	5,560	5,560
Accounts receivable, net	457,402	494,645
Inventory	775,818	719,316
Prepaid expenses	123,910	124,179
Other current assets	25,087	23,604
Total current assets	3,146,770	3,157,976
Property, plant, and equipment	1,538,545	1,508,020
Less: accumulated depreciation and amortization	1,027,156	1,009,408
Property, plant and equipment, net	511,389	498,612
Operating lease right-of-use assets	200,013	180,952
Goodwill, net	406,953	406,488
Purchased intangibles, net	314,187	332,147
Other investments	7,218,161	8,830,892
Other assets	98,470	94,599
Assets	11,895,943	13,501,666
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable	111,859	135,041
Accrued payroll and employee benefits	154,946	194,790
Current maturities of long-term debt and notes payable	476	465
Income and other taxes payable	103,978	32,428
Current operating lease liabilities	39,116	36,336
Other current liabilities	147,801	169,648
Total current liabilities	558,176	568,708
Long-term debt, net of current maturities	1,198,713	1,197,716
Deferred income taxes	1,369,556	1,770,481
Operating lease liabilities	167,179	153,597
Other long-term liabilities	186,121	195,912
Total liabilities	3,479,745	3,886,414
Stockholders' equity:
Additional paid-in capital	439,455	447,454
Retained earnings	8,910,921	9,898,203
Accumulated other comprehensive loss	(497,561)	(466,822)
Total stockholders' equity	8,416,198	9,615,252
Total liabilities and stockholders' equity	11,895,943	13,501,666
Common Class A [Member]
Stockholders' equity:
Common stock	2	2
Common Class B [Member]
Stockholders' equity:
Common stock	1	1
Treasury Class A [Member]
Stockholders' equity:
Treasury stock	$ (436,620)	$ (263,586)
Treasury Stock, Common
Stockholders' equity:
Treasury Stock, Shares	1,104,644	640,492

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets Parenthetical - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounts receivable allowance for doubtful accounts	$ 15,108	$ 15,029
Cash and cash equivalents	$ 457,850	$ 434,215
Common Class A [Member]
Common Stock, Shares, Issued	25,163,999	25,162,075
Common Stock, Shares, Outstanding	24,059,355	24,521,583
Common Class B [Member]
Common Stock, Shares, Issued	5,085,815	5,074,130
Common Stock, Shares, Outstanding	5,085,815	5,074,130

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net sales	$ 632,124	$ 680,800	$ 1,990,078	$ 2,071,961
Cost of goods sold	296,441	308,233	929,495	901,728
Gross profit	335,683	372,567	1,060,583	1,170,233
Selling, general and administrative expense	201,199	211,113	634,576	615,598
Research and Development Expense	43,535	66,808	183,528	190,689
Segment profit (loss)	90,949	94,646	242,479	363,946
Interest expense	12,398	11,663	37,078	26,431
Foreign exchange (gains) losses, net	(1,680)	4,364	(5,280)	3,133
Marketable Securities, Unrealized (Gain) Loss	(36,425)	288,999	1,576,542	6,172,306
Other Nonoperating Income (Expense)	20,446	3,062	87,365	42,369
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	137,102	(207,318)	(1,278,496)	(5,795,555)
(Provision) benefit for income taxes	(30,845)	44,510	291,464	1,340,286
Net income attributable to Bio-Rad	$ 106,257	$ (162,808)	$ (987,032)	$ (4,455,269)
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 3.65	$ (5.48)	$ (33.63)	$ (149.41)
Weighted average common shares - basic	29,102	29,733	29,349	29,819
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 3.64	$ (5.48)	$ (33.63)	$ (149.41)
Weighted average common shares - diluted	29,223	29,733	29,349	29,819

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net Income (Loss) Attributable to Parent	$ 106,257	$ (162,808)	$ (987,032)	$ (4,455,269)
Foreign currency translation adjustments	(126,165)	(305,666)	(34,342)	(653,301)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent	(342)	481	(72)	1,004
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense	1,808	(6,643)	3,675	(17,364)
Total other comprehensive income (loss) net of tax	(124,699)	(311,828)	(30,739)	(669,661)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ (18,442)	$ (474,636)	$ (1,017,771)	$ (5,124,930)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Cash received from customers	$ 2,007,482	$ 1,981,952
Cash paid to suppliers and employees	(1,722,173)	(1,800,487)
Interest paid, net	(46,394)	(23,974)
Income tax payments, net	(40,966)	(137,863)
Investment proceeds and miscellaneous receipts, net	81,828	51,146
Proceeds from forward foreign exchange contracts, net	14,119	44,016
Net cash provided by operating activities	293,896	114,790
Cash flows from investing activities:
Capital expenditures	(114,435)	(77,987)
Proceeds from dispositions of property, plant and equipment	104	114
Proceeds from Divestiture of Businesses	0	1,360
Payments for purchases of marketable securities and investments	(537,540)	(1,807,148)
Proceeds from maturities of marketable securities and investments	260,849	292,727
Proceeds from Sale of Debt Securities, Available-for-sale	339,033	542,639
Payments for Acquisitions, net of cash received	0	(100,746)
Net cash used in investing activities	(51,989)	(1,149,041)
Proceeds from Debt, Net of Issuance Costs	0	1,186,220
Cash flows from financing activities:
Payments on long-term borrowings	(349)	(367)
Proceeds from Issuance of Common Stock	14,168	13,218
Tax payments from net share settlement	(10,118)	(13,876)
Payments for purchases of treasury stock	(228,728)	(125,000)
Net cash used in financing activities	(225,027)	1,060,195
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	6,891	21,167
Beginning Cash, Cash Equivalents, and Restricted Cash	434,544	471,133
Cash and cash equivalents	457,850	517,943
Restricted Cash, Current	79	12
Restricted Cash, Noncurrent	386	289
Ending Cash, Cash Equivalents, and Restricted Cash	458,315	518,244
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$ 23,771	$ 47,111

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity Statement - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common	Retained Earnings [Member]	AOCI Attributable to Parent
Total Stockholders' Equity at Dec. 31, 2021	$ 13,685,236	$ 3	$ 441,733	$ (106,290)	$ 13,525,343	$ (175,553)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	(3,367,347)	0	0	0	(3,367,347)	0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(132,303)	0	0	0	0	(132,303)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	13,521	0	13,521	0	0	0
Proceeds from Issuance of Common Stock	(4,177)	0	(4,177)	0	0	0
Total Stockholders' Equity at Mar. 31, 2022	10,203,284	3	459,431	(106,290)	10,157,996	(307,856)
Total Stockholders' Equity at Dec. 31, 2021	13,685,236	3	441,733	(106,290)	13,525,343	(175,553)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	(4,455,269)
Proceeds from Issuance of Common Stock	(13,218)
Total Stockholders' Equity at Sep. 30, 2022	8,477,467	3	430,547	(178,261)	9,070,392	(845,214)
Total Stockholders' Equity at Mar. 31, 2022	10,203,284	3	459,431	(106,290)	10,157,996	(307,856)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	(925,114)	0	0	0	(925,114)	0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(225,530)	0	0	0	0	(225,530)
Stock Issued During Period, Value, New Issues	(443)	0	(443)	0	0	0
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	13,571	0	13,571	0	0	0
Treasury Stock Reissued at Lower than Repurchase Price	4,267	0	(696)	4,950	13	0
Treasury Stock, Value, Acquired, Cost Method	(125,000)			(125,000)
Total Stockholders' Equity at Jun. 30, 2022	8,945,035	3	471,863	(226,340)	9,232,895	(533,386)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	(162,808)	0	0	0	(162,808)	0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(311,828)	0	0	0	0	(311,828)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	15,735	0	15,735	0	0	0
Proceeds from Issuance of Common Stock	(7,550)	0	(7,550)	0	0	0
Treasury Stock Reissued at Lower than Repurchase Price	(1,117)	0	(49,501)	48,079	305	0
Total Stockholders' Equity at Sep. 30, 2022	8,477,467	3	430,547	(178,261)	9,070,392	(845,214)
Total Stockholders' Equity at Dec. 31, 2022	9,615,252	3	447,454	(263,586)	9,898,203	(466,822)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	68,962	0	0	0	68,962	0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	58,470	0	0	0	0	58,470
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	16,608	0	16,608	0	0	0
Total Stockholders' Equity at Mar. 31, 2023	9,763,716	3	463,402	(258,296)	9,966,959	(408,352)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Value, Treasury Stock Reissued	4,424	0	(660)	5,290	(206)	0
Total Stockholders' Equity at Dec. 31, 2022	9,615,252	3	447,454	(263,586)	9,898,203	(466,822)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	(987,032)
Proceeds from Issuance of Common Stock	(14,168)
Total Stockholders' Equity at Sep. 30, 2023	8,416,198	3	439,455	(436,620)	8,910,921	(497,561)
Total Stockholders' Equity at Mar. 31, 2023	9,763,716	3	463,402	(258,296)	9,966,959	(408,352)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	(1,162,251)	0	0	0	(1,162,251)	0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	35,490	0	0	0	0	35,490
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	12,559	0	12,559	0	0	0
Treasury Stock Reissued at Lower than Repurchase Price	(4,786)	0	(2,089)	(6,919)	(44)	0
Treasury Stock, Value, Acquired, Cost Method	(207,407)	0	0	(207,407)	0	0
Total Stockholders' Equity at Jun. 30, 2023	8,446,893	3	473,872	(458,784)	8,804,664	(372,862)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	106,257	0	0	0	106,257	0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(124,699)	0	0	0	0	(124,699)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	15,952	0	15,952	0	0	0
Proceeds from Issuance of Common Stock	5,111	0	5,111	0	0	0
Treasury Stock Reissued at Lower than Repurchase Price	(514)	0	45,258	(45,772)	0	0
Treasury Stock, Value, Acquired, Cost Method	(23,608)	0	0	(23,608)	0	0
Total Stockholders' Equity at Sep. 30, 2023	$ 8,416,198	$ 3	$ 439,455	$ (436,620)	$ 8,910,921	$ (497,561)

Basis of Presentation and Use o

Basis of Presentation and Use of Estimates	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Use of Estimates	1. BASIS OF PRESENTATION AND USE OF ESTIMATES Basis of Presentation In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022. We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions. Use of Estimates The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates. Revenue Recognition We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is allocated between separate performance obligations of an arrangement based on the standalone selling price for each distinct product or service. The method used to determine the standalone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately. We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed. At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Our reagent rental agreements provide our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification as operating or sales-type lease. The lease term used in performing the lease classification test, includes the noncancellable period of the lease together with those periods covered by lease extension options if the customer is reasonably certain to exercise that option, the periods covered by lease termination options if the customer is reasonably certain to not exercise that option, and the periods covered by the option to extend (or to not terminate) the lease when exercise of such option is controlled by the Company. The assessment of the lease term for reagent rental agreements, including the impact from any associated contractual termination penalties, is subject to an estimation process. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel the agreement, the period in which the contract is enforceable is very short so the lease term has been limited to the noncancellable period. Generally, these arrangements do not contain an option for the lessee to purchase the underlying asset. We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After we have allocated the transaction price to the lease and non-lease elements, the amount of variable payments allocated to such elements are recognized as income in accordance with ASC 842 or ASC 606, as applicable. Maintenance services and reagents are allocated to the non-lease elements. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial, and we do not enter into direct finance leases. Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three and nine months ended September 30, 2023 and September 30, 2022. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss). Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss). Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 United States $ 275.4 $ 284.1 $ 858.8 $ 848.2 EMEA 193.1 200.1 609.1 636.3 APAC 118.9 156.8 398.9 470.3 Other (primarily Canada and Latin America) 44.7 39.8 123.3 117.2 Total net sales $ 632.1 $ 680.8 $ 1,990.1 $ 2,072.0 The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11). Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at September 30, 2023 and December 31, 2022 was $66.5 million and $71.9 million, respectively. The short-term deferred revenue balance at September 30, 2023 and December 31, 2022 was $49.1 million and $52.2 million, respectively. We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss). Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the nine months ended September 30, 2023 and 2022 were as follows (in millions): Nine Months Ended September 30, 2023 2022 Balance at beginning of period $ 10.6 $ 12.7 Provision for warranty 6.4 6.7 Actual warranty costs (9.0) (8.8) Balance at end of period $ 8.0 $ 10.6 Accounts Receivable and Allowance for Credit Losses We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer. Changes in our allowance for credit losses were as follows (in millions): Nine Months Ended September 30, 2023 2022 Balance at beginning of period $ 15.0 $ 15.1 Provision for expected credit losses 0.9 1.2 Write-offs charged against the allowance (1.3) (2.3) Recoveries collected 0.5 0.1 Balance at end of period $ 15.1 $ 14.1 Recent Accounting Pronouncements Issued and to be Adopted

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	2. FAIR VALUE MEASUREMENTS We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1: Quoted prices in active markets for identical instruments • Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) • Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2023 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 7.5 $ — $ 7.5 Time deposits — 44.7 — 44.7 Money market funds 120.1 — — 120.1 Total cash equivalents (a) 120.1 52.2 — 172.3 Restricted investments (b) 6.9 — — 6.9 Equity securities (c) 6,947.6 — — 6,947.6 Loan under the fair value option (d) — — 290.5 290.5 Available-for-sale investments: Corporate debt securities — 590.6 — 590.6 U.S. government sponsored agencies — 283.7 — 283.7 Foreign government obligations — 10.0 — 10.0 Municipal obligations — 13.9 — 13.9 Asset-backed securities — 342.5 — 342.5 Total available-for-sale investments (e) — 1,240.7 — 1,240.7 Forward foreign exchange contracts (f) — 0.7 — 0.7 Total financial assets carried at fair value $ 7,074.6 $ 1,293.6 $ 290.5 $ 8,658.7 Financial liabilities carried at fair value: Forward foreign exchange contracts (g) $ — $ 1.0 $ — $ 1.0 Contingent consideration (h) — — 17.1 17.1 Total financial liabilities carried at fair value $ — $ 1.0 $ 17.1 $ 18.1 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2022 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 21.1 $ — $ 21.1 Time deposits 5.7 — — 5.7 Asset-backed securities — 1.4 — 1.4 U.S. government sponsored agencies — 6.0 — 6.0 Money market funds 31.5 — — 31.5 Total cash equivalents (a) 37.2 28.5 — 65.7 Restricted investments (b) 6.8 — — 6.8 Equity securities (c) 8,530.4 — — 8,530.4 Loan under the fair value option (d) — — 322.6 322.6 Available-for-sale investments: Corporate debt securities — 699.3 — 699.3 U.S. government sponsored agencies — 230.7 — 230.7 Foreign government obligations — 13.5 — 13.5 Municipal obligations — 23.1 — 23.1 Asset-backed securities — 333.4 — 333.4 Total available-for-sale investments (e) — 1,300.0 — 1,300.0 Forward foreign exchange contracts (f) — 1.5 — 1.5 Total financial assets carried at fair value $ 8,574.4 $ 1,330.0 $ 322.6 $ 10,227.0 Financial liabilities carried at fair value: Forward foreign exchange contracts (g) $ — $ 6.2 $ — $ 6.2 Contingent consideration (h) — — 35.6 35.6 Total financial liabilities carried at fair value $ — $ 6.2 $ 35.6 $ 41.8 (a) Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets. (b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2023 December 31, 2022 Restricted investments $ 5.6 $ 5.6 Other investments 1.3 1.2 Total $ 6.9 $ 6.8 (c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2023 December 31, 2022 Short-term investments $ 60.3 $ 56.5 Other investments 6,887.3 8,473.9 Total $ 6,947.6 $ 8,530.4 (d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. (e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets. (f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets. (g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets. (h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.8 million and $4.1 million in the consolidated statements of income (loss) for the three months ended September 30, 2023, respectively. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.4 million and $4.1 million in the consolidated statements of income (loss) for the nine months ended September 30, 2023, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2023. Level 1 Fair Value Measurements As of September 30, 2023, we own 12,987,900 ordinary voting shares and 9,588,908 preferenc e shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the ordinary outstanding shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of September 30, 2023. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting. The changes in fair market value of our investment in Sartorius for the three and nine months ended September 30, 2023 was a gain of $42.5 million and a loss of $1,556.1 million respectively, which is recorded in our condensed consolidated statements of income (loss). Level 2 Fair Value Measurements To estimate the fair value of Level 2 debt securities as of September 30, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. Available-for-sale investments consist of the following (in millions): September 30, 2023 Amortized Unrealized Unrealized Estimated Short-term investments: Corporate debt securities $ 598.0 $ 0.3 $ (7.7) $ 590.6 Municipal obligations 14.1 — (0.2) 13.9 Asset-backed securities 347.3 — (4.8) 342.5 U.S. government sponsored agencies 287.1 — (3.4) 283.7 Foreign government obligations 10.2 — (0.2) 10.0 $ 1,256.7 $ 0.3 $ (16.3) $ 1,240.7 The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2023 by contractual maturity date (in millions): Amortized Estimated Fair Mature in less than one year $ 473.6 $ 469.5 Mature in one to five years 636.7 627.8 Mature in more than five years 146.4 143.4 Total $ 1,256.7 $ 1,240.7 Available-for-sale investments consist of the following (in millions): December 31, 2022 Amortized Unrealized Unrealized Estimated Short-term investments: Corporate debt securities $ 709.9 $ 0.2 $ (10.8) $ 699.3 Municipal obligations 23.4 — (0.3) 23.1 Asset-backed securities 339.6 0.1 (6.3) 333.4 U.S. government sponsored agencies 233.9 — (3.2) 230.7 Foreign government obligations 13.8 — (0.3) 13.5 Total $ 1,320.6 $ 0.3 $ (20.9) $ 1,300.0 As of September 30, 2023, there were no significant continuous unrealized losses greater than 12 months. Our evaluation of credit losses for available-for-sale investments included t he extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis. At September 30, 2023, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of September 30, 2023. Included in Other current assets are $11.2 million and $11.6 million of interest receivable as of September 30, 2023 and December 31, 2022, respectively, primarily associated with securities in our available-for-sale investments portfolio. The interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the nine months ended September 30, 2023, we have not written-off any uncollected interest receivable. As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of September 30, 2023 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the related receivables and payables, both of which are included in Foreign currency exchange (gains) losses, net in the condensed consolidated statements of income (loss). The following is a summary of our forward foreign exchange contracts (in millions): September 30, 2023 Contracts maturing in October through December 2023 to sell foreign currency: Notional value $ 701.5 Unrealized loss $ (0.4) Contracts maturing in October through December 2023 to purchase foreign currency: Notional value $ 80.1 Unrealized gain $ 0.1 Level 3 Fair Value Investments During the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of €400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity (the “Loan”). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust (“Trust”) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and value appreciation right, including accrued interest are recognized in (Gains) losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income (loss). The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the three months ended September 30, 2023 was a loss of $4.9 million, which includes a $10.8 million loss from change in fair market value of the Loan and a $5.9 million gain from change in fair market value of the value appreciation right. The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the nine months ended September 30, 2023 was a loss of $28.9 million, which includes a $0.4 million loss from change in fair market value of the Loan and a $28.5 million loss from change in fair market value of the value appreciation right. The decrease in the fair market value of the value appreciation right was due to a decline in the value of the Sartorius ordinary shares. As of September 30, 2023, the €400 million principal amount of the loan is still due on January 31, 2029. The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions): December 31, 2022 $ 322.6 Net decrease in estimated fair market value of the loan included in (Gains) losses in fair market value of equity securities and loan receivable $ (28.9) Foreign currency exchange gains (losses), net $ (3.2) September 30, 2023 $ 290.5

Goodwill and Other Purchased In

Goodwill and Other Purchased Intangible Assets	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Purchased Intangible Assets	3. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS Changes to goodwill by segment are as follows (in millions): Life Clinical Total Balances as of December 31, 2022: Goodwill $ 333.3 $ 408.4 $ 741.7 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net 291.5 115.0 406.5 Acquisitions — 0.4 0.4 Foreign currency adjustments — 0.1 0.1 Period increase, net — 0.5 0.5 Balances as of September 30, 2023: Goodwill 333.3 408.9 742.2 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net $ 291.5 $ 115.5 $ 407.0 Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions): September 30, 2023 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.2 $ 104.3 $ (93.6) $ 10.7 Know how 2.0 165.1 (156.2) 8.9 Developed product technology 12.2 215.5 (128.4) 87.1 Licenses 5.1 58.8 (41.1) 17.7 Tradenames 5.8 6.0 (4.5) 1.5 Covenants not to compete 2.5 6.5 (4.7) 1.8 Total finite-lived intangible assets 556.2 (428.5) 127.7 In-process research and development 186.5 — 186.5 Total purchased intangible assets $ 742.7 $ (428.5) $ 314.2 December 31, 2022 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.0 $ 104.7 $ (89.9) $ 14.8 Know how 2.8 166.2 (153.9) 12.3 Developed product technology 12.8 211.1 (121.6) 89.5 Licenses 5.8 59.0 (38.5) 20.5 Tradenames 6.6 6.1 (4.5) 1.6 Covenants not to compete 3.1 6.4 (4.0) 2.4 Total finite-lived intangible assets 553.5 (412.4) 141.1 In-process research and development 191.0 — 191.0 Total purchased intangible assets $ 744.5 $ (412.4) $ 332.1 Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Amortization expense $ 6.2 $ 6.2 $ 18.1 $ 18.8

Inventory

Inventory	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventory	4. INVENTORY Following are the components of Inventory at September 30, 2023 and December 31, 2022 (in millions): September 30, 2023 December 31, 2022 Inventory: Raw materials $ 230.4 $ 228.8 Work in process 244.5 220.9 Finished goods 300.9 269.6 Total Inventory $ 775.8 $ 719.3

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	5. SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net loss to net cash provided by operating activities is as follows (in millions): Nine Months Ended September 30, 2023 September 30, 2022 Net loss $ (987.0) $ (4,455.3) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and amortization 108.7 101.8 Reduction in the carrying amount of right-of-use assets 30.7 29.8 Share-based compensation 45.1 42.8 Losses from change in fair market value of equity securities and loan receivable 1,576.5 6,172.3 Gain on divestiture of a division — (1.4) Changes in fair value of contingent consideration (18.5) — Payments for operating lease liabilities (30.4) (28.1) (Increase) decrease in accounts receivable 31.6 (44.5) Increase in inventories (61.7) (150.6) (Increase) decrease in other current assets 15.0 (11.9) Decrease in accounts payable and other current liabilities (72.4) (69.7) Increase (decrease) in income taxes payable 56.4 (39.2) Decrease in deferred income taxes (397.4) (1,439.1) Increase (decrease) in other long-term liabilities 3.9 (2.0) Other (6.6) 9.9 Net cash provided by operating activities $ 293.9 $ 114.8 Non-cash investing activities: Purchased property, plant and equipment $ 2.9 $ 3.3 Purchased marketable securities and investments $ — $ 11.8

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Long-term Debt	6. LONG-TERM DEBT The principal components of long-term debt are as follows (in millions): September 30, December 31, 3.3%, Senior Notes due 2027 $ 400.0 $ 400.0 3.7%, Senior Notes due 2032 800.0 800.0 Less unamortized discounts and debt issuance costs (11.0) (12.4) Long-term debt less unamortized discounts and debt issuance costs 1,189.0 1,187.6 Finance leases and other debt 10.2 10.6 Less current maturities (0.5) (0.5) Long-term debt $ 1,198.7 $ 1,197.7

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	7. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of December 31, 2022: $ (466.5) $ 10.0 $ (10.3) $ (466.8) Other comprehensive income (loss), before reclassifications (34.4) 0.3 3.7 (30.4) Amounts reclassified from Accumulated other comprehensive income (loss) — (0.4) 1.1 0.7 Income tax effects 0.1 — (1.1) (1.0) Other comprehensive income (loss), net of income taxes (34.3) (0.1) 3.7 (30.7) Balances as of September 30, 2023: $ (500.8) $ 9.9 $ (6.6) $ (497.5) Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of December 31, 2021: $ (170.5) $ (10.9) $ 5.8 $ (175.6) Other comprehensive income (loss), before reclassifications (654.4) 1.4 (23.3) (676.3) Amounts reclassified from Accumulated other comprehensive income (loss) — 0.2 0.6 0.8 Income tax effects 1.1 (0.5) 5.3 5.9 Other comprehensive income (loss), net of income taxes (653.3) 1.1 (17.4) (669.6) Balances as of September 30, 2022: $ (823.8) $ (9.8) $ (11.6) $ (845.2) All amounts reclassified out of accumulated other comprehensive income (loss) were reclassified into other income, net in the condensed consolidated statements of income (loss). The reclassification adjustments are calculated using the specific identification method. The impact to income (loss) before income taxes for amounts reclassified out of accumulated other comprehensive income (loss) into other income, net in the condensed consolidated statements of income (loss) were as follows (in millions):

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	8. EARNINGS (LOSS) PER SHARE Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B). Each share of Class A and Class B common stock participates equally in the earnings and losses of Bio-Rad, and each share is identical to the next in all respects except as follows. Class A common stock has limited voting rights compared to Class B. Each share of Class A is entitled to one tenth of a vote on most matters, whereas each share of Class B is always entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares. In contrast, no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder. We compute net income (loss) per share of Class A Common Stock (Class A) and Class B Common Stock (Class B) using the two-class method required for participating securities. Our participating securities include Class A and Class B. Each share of Class A and Class B participates equally in earnings and losses, but may not participate equally in dividend distributions. No dividends were distributed or declared during any of the periods presented. Earnings (loss) is attributable equally to each share of Class A and Class B common stock and is determined based on the weighted average number of the respective class of common stock outstanding for the three and nine months ended September 30, 2023 and 2022. Accordingly, basic earnings (loss) per share is computed by dividing net income (loss) attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options, restricted stock and performance stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings (loss) per share calculation if the effect of including such securities would be anti-dilutive. The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Basic weighted average shares outstanding 29,102 29,733 29,349 29,819 Effect of potentially dilutive stock options, restricted stock and performance stock awards 121 — — — Diluted weighted average common shares outstanding 29,223 29,733 29,349 29,819 Anti-dilutive shares 154 541 229 541

Other Income, Net

Other Income, Net	9 Months Ended
	Sep. 30, 2023
Other Income and Expenses [Abstract]
Other Income, Net	9. OTHER INCOME, NET Other income, net includes the following components (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Interest and investment income $ (17.3) $ (8.0) $ (84.1) $ (45.7) Net realized losses on investments 0.1 0.2 1.6 0.6 Current expected credit losses on loans — 5.1 — 5.1 Gain on divestiture of a division — — — (1.4) Escrow receipts on prior acquisition (2.5) — (2.5) — Other income (0.7) (0.4) (2.4) (1.0) Other income, net $ (20.4) $ (3.1) $ (87.4) $ (42.4)

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	10. INCOME TAXES Our effective income tax rate was 22.5% and 21.5% for the three months ended September 30, 2023 and 2022, respectively. Our effective income tax rate was 22.8% and 23.1% for the nine months ended September 30, 2023 and 2022, respectively. The realization of deferred tax assets are dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain of our federal, state and foreign deferred tax assets will not be realized as of September 30, 2023, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our federal, state and foreign deferred tax assets increased by $15.2 million for the period ended September 30, 2023 compared to the year ended December 31, 2022. Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. Our gross unrecognized tax benefits were $92.0 million and $85.5 million as of September 30, 2023 and December 31, 2022, respectively. The increase in our gross unrecognized tax benefits is primarily attributable to an increase of uncertain tax accruals in various jurisdictions. As of September 30, 2023, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $18.8 million. Substantially all such amounts will impact our effective income tax rate if recognized.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment Information	11. SEGMENT INFORMATION Information regarding operating profit (loss) for the three months ended September 30, 2023 and 2022 is as follows (in millions): Life Clinical Other Net sales 2023 $ 263.5 $ 368.1 $ 0.5 2022 $ 317.9 $ 361.9 $ 1.0 Operating profit (loss) 2023 $ 13.0 $ 78.0 $ (0.1) 2022 $ 51.4 $ 43.9 $ (0.7) Information regarding operating profit (loss) for the nine months ended September 30, 2023 and 2022 is as follows (in millions): Life Clinical Other Net sales 2023 $ 887.3 $ 1,100.3 $ 2.5 2022 $ 987.5 $ 1,081.4 $ 3.1 Operating profit (loss) 2023 $ 76.7 $ 166.1 $ (0.3) 2022 $ 197.6 $ 167.8 $ (1.5) Segment results are presented in the same manner as we manage our business internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses and corporate overhead as directly supporting the strategies of our segments, and these costs are fully allocated to our reportable segments. The following reconciles total segment profit to consolidated loss before income taxes (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Operating profit $ 90.9 $ 94.6 $ 242.5 $ 363.9 Interest expense (12.3) (11.6) (37.2) (26.5) Foreign currency exchange gains (losses), net 1.7 (4.4) 5.3 (3.1) Change in fair market value of equity securities and loan receivable 36.4 (289.0) (1,576.5) (6,172.3) Other income, net 20.4 3.1 87.4 42.4 Consolidated income (loss) before income taxes $ 137.1 $ (207.3) $ (1,278.5) $ (5,795.6)

Legal Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	12. LEGAL PROCEEDINGSWe are a party to various claims, legal actions and complaints arising in the ordinary course of business. We record a reserve when we believe a loss arising from these matters is probable and can be reasonably estimated. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. As additional information becomes available, any potential liability related to these matters is assessed and the estimates revised. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

Restructuring Costs

Restructuring Costs	9 Months Ended
	Sep. 30, 2023
Restructuring Costs [Abstract]
Restructuring Costs	13. RESTRUCTURING COSTS In February 2021, we announced a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacted our operations in EMEA and included the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from EMEA to APAC. The restructuring plan was implemented in phases and is substantially complete as of September 30, 2023. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. The adjustments to expense recorded were primarily due to changes in the estimates of employee termination benefits. From February 2021 to September 30, 2023, total expenses were $70.0 million. The following table summarizes the activity of our February 2021 plan restructuring reserves (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2022: $ 1.9 $ 29.7 $ 31.6 Adjustment to expense — 1.4 1.4 Cash payments (1.6) (16.5) (18.1) Foreign currency adjustments — (0.1) (0.1) Balances as of September 30, 2023: $ 0.3 $ 14.5 $ 14.8 In February 2023, management approved a new restructuring plan to implement identified opportunities to further streamline and improve operating performance. The additional restructuring activities are being implemented in phases and are expected to be substantially complete by the end of 2023. From February 2023 to September 30, 2023, total expenses were $15.4 million, representing estimated termination benefits to employees. The following table summarizes the activity of our February 2023 plan restructuring reserves (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2022: $ — $ — $ — Charged to expense - employee termination benefits 3.3 12.1 15.4 Cash payments (1.4) (3.8) (5.2) Foreign currency adjustments 0.1 0.1 0.2 Balances as of September 30, 2023: $ 2.0 $ 8.4 $ 10.4 In June 2023, management approved an additional restructuring plan to implement identified opportunities to further streamline and improve operating performance. The additional restructuring activities are expected to be substantially complete by the end of 2023. From June 2023 to September 30, 2023, total expenses were $9.0 million, representing estimated termination benefits to employees. The following table summarizes the activity of our June 2023 plan restructuring reserves (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2022: $ — $ — $ — Charged to expense - employee termination benefits 4.3 4.7 9.0 Cash payments (2.9) (1.8) (4.7) Foreign currency adjustments — — — Balances as of September 30, 2023: $ 1.4 $ 2.9 $ 4.3 Combined, the liability of $29.5 million as of September 30, 2023 consisted of $29.0 million recorded in Accrued payroll and employee benefits and $0.5 million recorded in Other long-term liabilities in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the three months ended September 30, 2023 were $0.2 million, $1.3 million and $0.0 million, respectively, in the condensed consolidated statements of income (loss). The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the nine months ended September 30, 2023 were $3.9 million, $16.6 million and $5.3 million, respectively, in the condensed consolidated statements of income (loss).

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Leases	14. LEASES We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 16 years, which includes our determination to exercise renewal options. We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our condensed consolidated balance sheets. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our condensed consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components. The components of lease expense were as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Operating lease cost $ 15.7 $ 14.2 $ 47.2 $ 43.2 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.1 $ 0.3 $ 0.3 Interest on lease liabilities 0.2 0.2 0.6 0.6 Total finance lease cost $ 0.3 $ 0.3 $ 0.9 $ 0.9 Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments. Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the three and nine months ended September 30, 2023 and 2022. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the three and nine months ended September 30, 2023 and 2022. Supplemental cash flow information related to leases was as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 10.6 $ 9.5 $ 30.4 $ 28.1 Operating cash flows from finance leases $ 0.2 $ 0.2 $ 0.6 $ 0.6 Financing cash flows from finance leases $ 0.1 $ 0.1 $ 0.3 $ 0.3 Right-of-use assets obtained in exchange for new lease obligations: Operating leases $ 36.7 $ 2.3 $ 49.0 $ 9.4 Supplemental balance sheet information related to leases was as follows (in millions): September 30, 2023 December 31, 2022 Operating Leases Operating lease right-of-use assets $ 200.0 $ 181.0 Current operating lease liabilities $ 39.1 $ 36.3 Operating lease liabilities 167.2 153.6 Total operating lease liabilities $ 206.3 $ 189.9 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions): September 30, 2023 December 31, 2022 Finance Leases Property, plant and equipment, gross $ 11.8 $ 11.9 Less: accumulated depreciation and amortization (5.7) (5.5) Property, plant and equipment, net $ 6.1 $ 6.4 Current maturities of long-term debt and notes payable $ 0.5 $ 0.5 Long-term debt, net of current maturities 9.7 10.1 Total finance lease liabilities $ 10.2 $ 10.6 September 30, 2023 December 31, 2022 Weighted Average Remaining Lease Term Operating leases - in years 7 7 Finance leases - in years 14 15 Weighted Average Discount Rate Operating leases 3.8 % 3.0 % Finance leases 6.4 % 6.3 % Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2023 (excluding the nine months ended September 30, 2023) $ 10.4 $ 0.3 2024 45.5 1.2 2025 42.6 1.1 2026 31.2 1.1 2027 24.7 1.1 Thereafter 82.7 11.9 Total lease payments 237.1 16.7 Less imputed interest (30.8) (6.5) Total $ 206.3 $ 10.2 The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher turn-over. As of September 30, 2023, operating leases that have not commenced are not material.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss) Attributable to Parent	$ 106,257	$ (1,162,251)	$ 68,962	$ (162,808)	$ (925,114)	$ (3,367,347)	$ (987,032)	$ (4,455,269)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Basis of Presentation and Use_2

Basis of Presentation and Use of Estimates (Policies)	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022.
Subsequent Events, Policy	We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates.
Revenue Recognition	Revenue Recognition We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is allocated between separate performance obligations of an arrangement based on the standalone selling price for each distinct product or service. The method used to determine the standalone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately. We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed. At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Our reagent rental agreements provide our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification as operating or sales-type lease. The lease term used in performing the lease classification test, includes the noncancellable period of the lease together with those periods covered by lease extension options if the customer is reasonably certain to exercise that option, the periods covered by lease termination options if the customer is reasonably certain to not exercise that option, and the periods covered by the option to extend (or to not terminate) the lease when exercise of such option is controlled by the Company. The assessment of the lease term for reagent rental agreements, including the impact from any associated contractual termination penalties, is subject to an estimation process. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel the agreement, the period in which the contract is enforceable is very short so the lease term has been limited to the noncancellable period. Generally, these arrangements do not contain an option for the lessee to purchase the underlying asset. We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After we have allocated the transaction price to the lease and non-lease elements, the amount of variable payments allocated to such elements are recognized as income in accordance with ASC 842 or ASC 606, as applicable. Maintenance services and reagents are allocated to the non-lease elements. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial, and we do not enter into direct finance leases. Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three and nine months ended September 30, 2023 and September 30, 2022. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss). Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss). Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 United States $ 275.4 $ 284.1 $ 858.8 $ 848.2 EMEA 193.1 200.1 609.1 636.3 APAC 118.9 156.8 398.9 470.3 Other (primarily Canada and Latin America) 44.7 39.8 123.3 117.2 Total net sales $ 632.1 $ 680.8 $ 1,990.1 $ 2,072.0 The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11). Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at September 30, 2023 and December 31, 2022 was $66.5 million and $71.9 million, respectively. The short-term deferred revenue balance at September 30, 2023 and December 31, 2022 was $49.1 million and $52.2 million, respectively.
Standard Product Warranty, Policy	We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss). Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the nine months ended September 30, 2023 and 2022 were as follows (in millions): Nine Months Ended September 30, 2023 2022 Balance at beginning of period $ 10.6 $ 12.7 Provision for warranty 6.4 6.7 Actual warranty costs (9.0) (8.8) Balance at end of period $ 8.0 $ 10.6
Accounts Receivable and Allowance for Credit Losses	Accounts Receivable and Allowance for Credit Losses We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer. Changes in our allowance for credit losses were as follows (in millions): Nine Months Ended September 30, 2023 2022 Balance at beginning of period $ 15.0 $ 15.1 Provision for expected credit losses 0.9 1.2 Write-offs charged against the allowance (1.3) (2.3) Recoveries collected 0.5 0.1 Balance at end of period $ 15.1 $ 14.1
Recent Accounting Pronouncements Issued and to be Adopted	Recent Accounting Pronouncements Issued and to be AdoptedThere are no new accounting pronouncements recently issued or newly effective that had, or are expected to have, a material impact on the Company's condensed consolidated financial statements.

1. Basis of Presentation and Us

1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenue from External Customers by Geographic Areas [Table Text Block]	The following table presents our revenues disaggregated by geographic region (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 United States $ 275.4 $ 284.1 $ 858.8 $ 848.2 EMEA 193.1 200.1 609.1 636.3 APAC 118.9 156.8 398.9 470.3 Other (primarily Canada and Latin America) 44.7 39.8 123.3 117.2 Total net sales $ 632.1 $ 680.8 $ 1,990.1 $ 2,072.0
Schedule of Product Warranty Liability [Table Text Block]	Change in our warranty liability for the nine months ended September 30, 2023 and 2022 were as follows (in millions): Nine Months Ended September 30, 2023 2022 Balance at beginning of period $ 10.6 $ 12.7 Provision for warranty 6.4 6.7 Actual warranty costs (9.0) (8.8) Balance at end of period $ 8.0 $ 10.6
Accounts Receivable, Allowance for Credit Loss [Table Text Block]	Changes in our allowance for credit losses were as follows (in millions): Nine Months Ended September 30, 2023 2022 Balance at beginning of period $ 15.0 $ 15.1 Provision for expected credit losses 0.9 1.2 Write-offs charged against the allowance (1.3) (2.3) Recoveries collected 0.5 0.1 Balance at end of period $ 15.1 $ 14.1

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements, Recurring and Nonrecurring	Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2023 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 7.5 $ — $ 7.5 Time deposits — 44.7 — 44.7 Money market funds 120.1 — — 120.1 Total cash equivalents (a) 120.1 52.2 — 172.3 Restricted investments (b) 6.9 — — 6.9 Equity securities (c) 6,947.6 — — 6,947.6 Loan under the fair value option (d) — — 290.5 290.5 Available-for-sale investments: Corporate debt securities — 590.6 — 590.6 U.S. government sponsored agencies — 283.7 — 283.7 Foreign government obligations — 10.0 — 10.0 Municipal obligations — 13.9 — 13.9 Asset-backed securities — 342.5 — 342.5 Total available-for-sale investments (e) — 1,240.7 — 1,240.7 Forward foreign exchange contracts (f) — 0.7 — 0.7 Total financial assets carried at fair value $ 7,074.6 $ 1,293.6 $ 290.5 $ 8,658.7 Financial liabilities carried at fair value: Forward foreign exchange contracts (g) $ — $ 1.0 $ — $ 1.0 Contingent consideration (h) — — 17.1 17.1 Total financial liabilities carried at fair value $ — $ 1.0 $ 17.1 $ 18.1 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2022 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 21.1 $ — $ 21.1 Time deposits 5.7 — — 5.7 Asset-backed securities — 1.4 — 1.4 U.S. government sponsored agencies — 6.0 — 6.0 Money market funds 31.5 — — 31.5 Total cash equivalents (a) 37.2 28.5 — 65.7 Restricted investments (b) 6.8 — — 6.8 Equity securities (c) 8,530.4 — — 8,530.4 Loan under the fair value option (d) — — 322.6 322.6 Available-for-sale investments: Corporate debt securities — 699.3 — 699.3 U.S. government sponsored agencies — 230.7 — 230.7 Foreign government obligations — 13.5 — 13.5 Municipal obligations — 23.1 — 23.1 Asset-backed securities — 333.4 — 333.4 Total available-for-sale investments (e) — 1,300.0 — 1,300.0 Forward foreign exchange contracts (f) — 1.5 — 1.5 Total financial assets carried at fair value $ 8,574.4 $ 1,330.0 $ 322.6 $ 10,227.0 Financial liabilities carried at fair value: Forward foreign exchange contracts (g) $ — $ 6.2 $ — $ 6.2 Contingent consideration (h) — — 35.6 35.6 Total financial liabilities carried at fair value $ — $ 6.2 $ 35.6 $ 41.8 (a) Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets. (b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2023 December 31, 2022 Restricted investments $ 5.6 $ 5.6 Other investments 1.3 1.2 Total $ 6.9 $ 6.8 (c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2023 December 31, 2022 Short-term investments $ 60.3 $ 56.5 Other investments 6,887.3 8,473.9 Total $ 6,947.6 $ 8,530.4 (d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. (e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets. (f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets. (g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets. (h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.8 million and $4.1 million in the consolidated statements of income (loss) for the three months ended September 30, 2023, respectively. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.4 million and $4.1 million in the consolidated statements of income (loss) for the nine months ended September 30, 2023, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2023.
Debt Securities, Available-for-sale	Available-for-sale investments consist of the following (in millions): September 30, 2023 Amortized Unrealized Unrealized Estimated Short-term investments: Corporate debt securities $ 598.0 $ 0.3 $ (7.7) $ 590.6 Municipal obligations 14.1 — (0.2) 13.9 Asset-backed securities 347.3 — (4.8) 342.5 U.S. government sponsored agencies 287.1 — (3.4) 283.7 Foreign government obligations 10.2 — (0.2) 10.0 $ 1,256.7 $ 0.3 $ (16.3) $ 1,240.7 Available-for-sale investments consist of the following (in millions): December 31, 2022 Amortized Unrealized Unrealized Estimated Short-term investments: Corporate debt securities $ 709.9 $ 0.2 $ (10.8) $ 699.3 Municipal obligations 23.4 — (0.3) 23.1 Asset-backed securities 339.6 0.1 (6.3) 333.4 U.S. government sponsored agencies 233.9 — (3.2) 230.7 Foreign government obligations 13.8 — (0.3) 13.5 Total $ 1,320.6 $ 0.3 $ (20.9) $ 1,300.0
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date	The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2023 by contractual maturity date (in millions): Amortized Estimated Fair Mature in less than one year $ 473.6 $ 469.5 Mature in one to five years 636.7 627.8 Mature in more than five years 146.4 143.4 Total $ 1,256.7 $ 1,240.7
Discussion of current derivative risk management	The following is a summary of our forward foreign exchange contracts (in millions): September 30, 2023 Contracts maturing in October through December 2023 to sell foreign currency: Notional value $ 701.5 Unrealized loss $ (0.4) Contracts maturing in October through December 2023 to purchase foreign currency: Notional value $ 80.1 Unrealized gain $ 0.1
Fair Value Measurement Inputs and Valuation Techniques	The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions): December 31, 2022 $ 322.6 Net decrease in estimated fair market value of the loan included in (Gains) losses in fair market value of equity securities and loan receivable $ (28.9) Foreign currency exchange gains (losses), net $ (3.2) September 30, 2023 $ 290.5

Goodwill and Other Purchased _2

Goodwill and Other Purchased Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Changes to goodwill by segment	Changes to goodwill by segment are as follows (in millions): Life Clinical Total Balances as of December 31, 2022: Goodwill $ 333.3 $ 408.4 $ 741.7 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net 291.5 115.0 406.5 Acquisitions — 0.4 0.4 Foreign currency adjustments — 0.1 0.1 Period increase, net — 0.5 0.5 Balances as of September 30, 2023: Goodwill 333.3 408.9 742.2 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net $ 291.5 $ 115.5 $ 407.0
Schedule of identifiable purchased intangible assets with definite lives	Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions): September 30, 2023 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.2 $ 104.3 $ (93.6) $ 10.7 Know how 2.0 165.1 (156.2) 8.9 Developed product technology 12.2 215.5 (128.4) 87.1 Licenses 5.1 58.8 (41.1) 17.7 Tradenames 5.8 6.0 (4.5) 1.5 Covenants not to compete 2.5 6.5 (4.7) 1.8 Total finite-lived intangible assets 556.2 (428.5) 127.7 In-process research and development 186.5 — 186.5 Total purchased intangible assets $ 742.7 $ (428.5) $ 314.2 December 31, 2022 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.0 $ 104.7 $ (89.9) $ 14.8 Know how 2.8 166.2 (153.9) 12.3 Developed product technology 12.8 211.1 (121.6) 89.5 Licenses 5.8 59.0 (38.5) 20.5 Tradenames 6.6 6.1 (4.5) 1.6 Covenants not to compete 3.1 6.4 (4.0) 2.4 Total finite-lived intangible assets 553.5 (412.4) 141.1 In-process research and development 191.0 — 191.0 Total purchased intangible assets $ 744.5 $ (412.4) $ 332.1
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Amortization expense $ 6.2 $ 6.2 $ 18.1 $ 18.8

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Following are the components of Inventory at September 30, 2023 and December 31, 2022 (in millions): September 30, 2023 December 31, 2022 Inventory: Raw materials $ 230.4 $ 228.8 Work in process 244.5 220.9 Finished goods 300.9 269.6 Total Inventory $ 775.8 $ 719.3

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures	The reconciliation of net loss to net cash provided by operating activities is as follows (in millions): Nine Months Ended September 30, 2023 September 30, 2022 Net loss $ (987.0) $ (4,455.3) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and amortization 108.7 101.8 Reduction in the carrying amount of right-of-use assets 30.7 29.8 Share-based compensation 45.1 42.8 Losses from change in fair market value of equity securities and loan receivable 1,576.5 6,172.3 Gain on divestiture of a division — (1.4) Changes in fair value of contingent consideration (18.5) — Payments for operating lease liabilities (30.4) (28.1) (Increase) decrease in accounts receivable 31.6 (44.5) Increase in inventories (61.7) (150.6) (Increase) decrease in other current assets 15.0 (11.9) Decrease in accounts payable and other current liabilities (72.4) (69.7) Increase (decrease) in income taxes payable 56.4 (39.2) Decrease in deferred income taxes (397.4) (1,439.1) Increase (decrease) in other long-term liabilities 3.9 (2.0) Other (6.6) 9.9 Net cash provided by operating activities $ 293.9 $ 114.8 Non-cash investing activities: Purchased property, plant and equipment $ 2.9 $ 3.3 Purchased marketable securities and investments $ — $ 11.8

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The principal components of long-term debt are as follows (in millions): September 30, December 31, 3.3%, Senior Notes due 2027 $ 400.0 $ 400.0 3.7%, Senior Notes due 2032 800.0 800.0 Less unamortized discounts and debt issuance costs (11.0) (12.4) Long-term debt less unamortized discounts and debt issuance costs 1,189.0 1,187.6 Finance leases and other debt 10.2 10.6 Less current maturities (0.5) (0.5) Long-term debt $ 1,198.7 $ 1,197.7

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of December 31, 2022: $ (466.5) $ 10.0 $ (10.3) $ (466.8) Other comprehensive income (loss), before reclassifications (34.4) 0.3 3.7 (30.4) Amounts reclassified from Accumulated other comprehensive income (loss) — (0.4) 1.1 0.7 Income tax effects 0.1 — (1.1) (1.0) Other comprehensive income (loss), net of income taxes (34.3) (0.1) 3.7 (30.7) Balances as of September 30, 2023: $ (500.8) $ 9.9 $ (6.6) $ (497.5) Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of December 31, 2021: $ (170.5) $ (10.9) $ 5.8 $ (175.6) Other comprehensive income (loss), before reclassifications (654.4) 1.4 (23.3) (676.3) Amounts reclassified from Accumulated other comprehensive income (loss) — 0.2 0.6 0.8 Income tax effects 1.1 (0.5) 5.3 5.9 Other comprehensive income (loss), net of income taxes (653.3) 1.1 (17.4) (669.6) Balances as of September 30, 2022: $ (823.8) $ (9.8) $ (11.6) $ (845.2)
Reclassification Out of Accumulated Other Comprehensive Income	The impact to income (loss) before income taxes for amounts reclassified out of accumulated other comprehensive income (loss) into other income, net in the condensed consolidated statements of income (loss) were as follows (in millions):

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares	The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Basic weighted average shares outstanding 29,102 29,733 29,349 29,819 Effect of potentially dilutive stock options, restricted stock and performance stock awards 121 — — — Diluted weighted average common shares outstanding 29,223 29,733 29,349 29,819 Anti-dilutive shares 154 541 229 541

Other Income, Net (Tables)

Other Income, Net (Tables)	9 Months Ended
	Sep. 30, 2023
Other Income and Expenses [Abstract]
Schedule of other income (expense), net	Other income, net includes the following components (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Interest and investment income $ (17.3) $ (8.0) $ (84.1) $ (45.7) Net realized losses on investments 0.1 0.2 1.6 0.6 Current expected credit losses on loans — 5.1 — 5.1 Gain on divestiture of a division — — — (1.4) Escrow receipts on prior acquisition (2.5) — (2.5) — Other income (0.7) (0.4) (2.4) (1.0) Other income, net $ (20.4) $ (3.1) $ (87.4) $ (42.4)

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Information regarding operating profit (loss) for the three months ended September 30, 2023 and 2022 is as follows (in millions): Life Clinical Other Net sales 2023 $ 263.5 $ 368.1 $ 0.5 2022 $ 317.9 $ 361.9 $ 1.0 Operating profit (loss) 2023 $ 13.0 $ 78.0 $ (0.1) 2022 $ 51.4 $ 43.9 $ (0.7) Information regarding operating profit (loss) for the nine months ended September 30, 2023 and 2022 is as follows (in millions): Life Clinical Other Net sales 2023 $ 887.3 $ 1,100.3 $ 2.5 2022 $ 987.5 $ 1,081.4 $ 3.1 Operating profit (loss) 2023 $ 76.7 $ 166.1 $ (0.3) 2022 $ 197.6 $ 167.8 $ (1.5)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following reconciles total segment profit to consolidated loss before income taxes (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Operating profit $ 90.9 $ 94.6 $ 242.5 $ 363.9 Interest expense (12.3) (11.6) (37.2) (26.5) Foreign currency exchange gains (losses), net 1.7 (4.4) 5.3 (3.1) Change in fair market value of equity securities and loan receivable 36.4 (289.0) (1,576.5) (6,172.3) Other income, net 20.4 3.1 87.4 42.4 Consolidated income (loss) before income taxes $ 137.1 $ (207.3) $ (1,278.5) $ (5,795.6)

Restructuring Costs (Tables)

Restructuring Costs (Tables)	9 Months Ended
	Sep. 30, 2023
Restructuring Costs [Abstract]
Restructuring and Related Costs	The following table summarizes the activity of our February 2021 plan restructuring reserves (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2022: $ 1.9 $ 29.7 $ 31.6 Adjustment to expense — 1.4 1.4 Cash payments (1.6) (16.5) (18.1) Foreign currency adjustments — (0.1) (0.1) Balances as of September 30, 2023: $ 0.3 $ 14.5 $ 14.8 The following table summarizes the activity of our February 2023 plan restructuring reserves (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2022: $ — $ — $ — Charged to expense - employee termination benefits 3.3 12.1 15.4 Cash payments (1.4) (3.8) (5.2) Foreign currency adjustments 0.1 0.1 0.2 Balances as of September 30, 2023: $ 2.0 $ 8.4 $ 10.4 The following table summarizes the activity of our June 2023 plan restructuring reserves (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2022: $ — $ — $ — Charged to expense - employee termination benefits 4.3 4.7 9.0 Cash payments (2.9) (1.8) (4.7) Foreign currency adjustments — — — Balances as of September 30, 2023: $ 1.4 $ 2.9 $ 4.3

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Lease, Cost	The components of lease expense were as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Operating lease cost $ 15.7 $ 14.2 $ 47.2 $ 43.2 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.1 $ 0.3 $ 0.3 Interest on lease liabilities 0.2 0.2 0.6 0.6 Total finance lease cost $ 0.3 $ 0.3 $ 0.9 $ 0.9
Lessee Supplemental Cash Flow Information	Supplemental cash flow information related to leases was as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 10.6 $ 9.5 $ 30.4 $ 28.1 Operating cash flows from finance leases $ 0.2 $ 0.2 $ 0.6 $ 0.6 Financing cash flows from finance leases $ 0.1 $ 0.1 $ 0.3 $ 0.3 Right-of-use assets obtained in exchange for new lease obligations: Operating leases $ 36.7 $ 2.3 $ 49.0 $ 9.4
Lessee Supplemental Balance Sheet Information	Supplemental balance sheet information related to leases was as follows (in millions): September 30, 2023 December 31, 2022 Operating Leases Operating lease right-of-use assets $ 200.0 $ 181.0 Current operating lease liabilities $ 39.1 $ 36.3 Operating lease liabilities 167.2 153.6 Total operating lease liabilities $ 206.3 $ 189.9 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions): September 30, 2023 December 31, 2022 Finance Leases Property, plant and equipment, gross $ 11.8 $ 11.9 Less: accumulated depreciation and amortization (5.7) (5.5) Property, plant and equipment, net $ 6.1 $ 6.4 Current maturities of long-term debt and notes payable $ 0.5 $ 0.5 Long-term debt, net of current maturities 9.7 10.1 Total finance lease liabilities $ 10.2 $ 10.6 September 30, 2023 December 31, 2022 Weighted Average Remaining Lease Term Operating leases - in years 7 7 Finance leases - in years 14 15 Weighted Average Discount Rate Operating leases 3.8 % 3.0 % Finance leases 6.4 % 6.3 %
Maturities Of Lease Liabilities For Operating and Finance Leases	Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2023 (excluding the nine months ended September 30, 2023) $ 10.4 $ 0.3 2024 45.5 1.2 2025 42.6 1.1 2026 31.2 1.1 2027 24.7 1.1 Thereafter 82.7 11.9 Total lease payments 237.1 16.7 Less imputed interest (30.8) (6.5) Total $ 206.3 $ 10.2

1. Basis of Presentation and _2

1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	$ 632,124	$ 680,800	$ 1,990,078	$ 2,071,961
Cost of goods sold	296,441	308,233	929,495	901,728
Deferred Revenue	66,500		66,500				$ 71,900
Retained earnings	8,910,921		8,910,921				9,898,203
Accumulated other comprehensive loss	(497,561)		(497,561)				(466,822)
Total stockholders' equity	$ 8,416,198	8,477,467	$ 8,416,198	8,477,467	$ 8,446,893	$ 9,763,716	9,615,252	$ 8,945,035	$ 10,203,284	$ 13,685,236
Revenue Allocation Percent To Lease Elements	3%		3%
Additional paid-in-capital	$ 439,455		$ 439,455				447,454
Selling, general and administrative expense	201,199	211,113	634,576	615,598
Research and Development Expense	43,535	66,808	183,528	190,689
Interest expense	12,398	11,663	37,078	26,431
Other Nonoperating Income (Expense)	20,446	3,062	87,365	42,369
Deferred Revenue, Current	49,100		49,100				$ 52,200
Europe [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	193,100	200,100	609,100	636,300
Asia Pacific [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	118,900	156,800	398,900	470,300
UNITED STATES
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	275,400	284,100	858,800	848,200
Americas [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	$ 44,700	$ 39,800	$ 123,300	$ 117,200

1. Basis of Presentation and _3

1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Warranty accrual, beginning of period	$ 10.6	$ 12.7
Provision for warranty	6.4	6.7
Actual warranty costs	(9)	(8.8)
Warranty accrual, end of period	$ 8	$ 10.6

1. Basis of Presentation and _4

1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts Receivable, Allowance for Credit Loss	$ 15.1	$ 14.1	$ 15	$ 15.1
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)	0.9	1.2
Allowance for Loan and Lease Losses, Write-offs	(1.3)	(2.3)
Accounts Receivable, Allowance for Credit Loss, Recovery	$ 0.5	$ 0.1

1. Basis of Presentation and _5

1. Basis of Presentation and Use of Estimates (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenue Allocation Percent To Lease Elements	3%	3%

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Millions		3 Months Ended	9 Months Ended
		Sep. 30, 2023	Sep. 30, 2023		Sep. 30, 2022	Dec. 31, 2022		Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain on Securities		$ 42.5
Debt Securities, Trading, and Equity Securities, FV-NI		290.5	$ 290.5			$ 322.6
Debt Securities, Available-for-sale	[1]	1,240.7	1,240.7
Fair Value, Option, Changes in Fair Value, Gain (Loss)		(4.9)	(28.9)
Foreign exchange (gains) losses, net			(3.2)
Fair Value, Option, Loans Held as Assets [Abstract]
Debt Securities	[2]							$ 400
Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions		10.8	0.4	[2]
Derivative, Forward Interest Rate								1.50%
Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract]
Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net		$ (5.9)	28.5	[2]
Equity Securities, FV-NI, Unrealized Loss			(1,556.1)
Changes in fair value of contingent consideration			$ (18.5)		$ 0
Ordinary voting shares [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment ownership percentage		38%	38%
Preference shares [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment ownership percentage		28%	28%
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[3]	$ 6.9	$ 6.9			6.8
Equity Securities	[4]	6,947.6	6,947.6			8,530.4
Debt Securities, Trading, and Equity Securities, FV-NI	[2]	290.5	290.5			322.6
Debt Securities, Available-for-sale	[1]	1,240.7	1,240.7			1,300
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[5]	0.7	0.7			1.5
Assets, Fair Value Disclosure		8,658.7	8,658.7			10,227
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[6]	1	1			6.2
Business Combination, Contingent Consideration, Liability	[7]	17.1	17.1			35.6
Liabilities, Fair Value Disclosure		18.1	18.1			41.8
Fair Value, Recurring | Research and Development Expense
Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract]
Changes in fair value of contingent consideration		14.8	14.4
Fair Value, Recurring | Selling, General and Administrative Expenses
Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract]
Changes in fair value of contingent consideration		4.1	4.1
Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[3]	6.9	6.9			6.8
Equity Securities	[4]	6,947.6	6,947.6			8,530.4
Debt Securities, Trading, and Equity Securities, FV-NI	[2]	0	0			0
Debt Securities, Available-for-sale	[1]	0	0			0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[5]	0	0			0
Assets, Fair Value Disclosure		7,074.6	7,074.6			8,574.4
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[6]	0	0			0
Business Combination, Contingent Consideration, Liability	[7]	0	0			0
Liabilities, Fair Value Disclosure		0	0			0
Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[3]	0	0			0
Equity Securities	[4]	0	0			0
Debt Securities, Trading, and Equity Securities, FV-NI	[2]	0	0			0
Debt Securities, Available-for-sale		1,240.7	1,240.7			1,300	[1]
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[5]	0.7	0.7			1.5
Assets, Fair Value Disclosure		1,293.6	1,293.6			1,330
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[6]	1	1			6.2
Business Combination, Contingent Consideration, Liability	[7]	0	0			0
Liabilities, Fair Value Disclosure		1	1			6.2
Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[3]	0	0			0
Equity Securities	[4]	0	0			0
Debt Securities, Trading, and Equity Securities, FV-NI	[2]	290.5	290.5			322.6
Debt Securities, Available-for-sale	[1]	0	0			0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[5]	0	0			0
Assets, Fair Value Disclosure		290.5	290.5			322.6
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[6]	0	0			0
Business Combination, Contingent Consideration, Liability	[7]	17.1	17.1			35.6
Liabilities, Fair Value Disclosure		17.1	17.1			35.6
Asset-backed Securities [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]					1.4
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]					0
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]					1.4
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]					0
Commercial Paper [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	7.5	7.5			21.1
Commercial Paper [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0	0			0
Commercial Paper [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	7.5	7.5			21.1
Commercial Paper [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0	0			0
Time Deposits [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	44.7	44.7			5.7
Time Deposits [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0	0			5.7
Time Deposits [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	44.7	44.7			0
Time Deposits [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0	0			0
Money Market Funds [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	120.1	120.1			31.5
Money Market Funds [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	120.1	120.1			31.5
Money Market Funds [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0	0			0
Money Market Funds [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0	0			0
Cash Equivalents [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	172.3	172.3			65.7
Cash Equivalents [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	120.1	120.1			37.2
Cash Equivalents [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	52.2	52.2			28.5
Cash Equivalents [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0	0			0
US Treasury Securities | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]					6
US Treasury Securities | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]					6
US Treasury Securities | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]					0
Foreign Government Debt [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]					0
Municipal Obligations (Member) | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	13.9	13.9			23.1
Municipal Obligations (Member) | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	0	0			0
Municipal Obligations (Member) | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	13.9	13.9			23.1
Municipal Obligations (Member) | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	0	0			0
Foreign Government Obligations [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	10	10			13.5
Foreign Government Obligations [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	0	0			0
Foreign Government Obligations [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	10	10			13.5
Foreign Government Obligations [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	0	0			0
Corporate Debt Securities [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	590.6	590.6			699.3
Corporate Debt Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	0	0			0
Corporate Debt Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	590.6	590.6			699.3
Corporate Debt Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	0	0			0
US Government Sponsored Agencies [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	283.7	283.7			230.7
US Government Sponsored Agencies [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	0	0			0
US Government Sponsored Agencies [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	283.7	283.7			230.7
US Government Sponsored Agencies [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	0	0			0
Asset-backed Securities [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	342.5	342.5			333.4
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	0	0			0
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	342.5	342.5			333.4
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	0	0			0
Short-term Investments [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	[4]	60.3	60.3			56.5
Debt Securities, Available-for-sale	[1]	1,240.7	1,240.7			1,300
Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	13.9	13.9			23.1
Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	10	10			13.5
Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	590.6	590.6			699.3
Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	283.7	283.7			230.7
Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[1]	342.5	342.5			333.4
Other Investments [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[3]	1.3	1.3			1.2
Equity Securities	[4]	6,887.3	6,887.3			8,473.9
Restricted investment [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[3]	$ 5.6	$ 5.6			$ 5.6
[1]Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.[2]The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.[3]Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2023 December 31, 2022 Restricted investments $ 5.6 $ 5.6 Other investments 1.3 1.2 Total $ 6.9 $ 6.8 September 30, 2023 December 31, 2022 Short-term investments $ 60.3 $ 56.5 Other investments 6,887.3 8,473.9 Total $ 6,947.6 $ 8,530.4

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - USD ($) $ in Millions		Sep. 30, 2023	Dec. 31, 2022
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	$ 17.1	$ 35.6
[1]Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.8 million and $4.1 million in the consolidated statements of income (loss) for the three months ended September 30, 2023, respectively. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.4 million and $4.1 million in the consolidated statements of income (loss) for the nine months ended September 30, 2023, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2023.

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) $ in Millions	3 Months Ended
	Sep. 30, 2023 USD ($)	[1]
Forward foreign exchange contract to sell foreign currency [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	$ 701.5
Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	(0.4)
Forward foreign exchange contract to purchase foreign currency [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	80.1
Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	$ 0.1
[1]Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.

Fair Value Measurements (Deta_4

Fair Value Measurements (Details) - USD ($) $ in Millions		Sep. 30, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	$ 1,256.7
Debt Securities, Available-for-sale	[1]	1,240.7
Fair Value, Recurring
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	1,240.7	$ 1,300
Fair Value, Recurring | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	590.6	699.3
Fair Value, Recurring | Municipal obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	13.9	23.1
Fair Value, Recurring | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	283.7	230.7
Fair Value, Recurring | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	10	13.5
Fair Value, Recurring | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	342.5	333.4
Fair Value, Recurring | Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	1,256.7	1,320.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[1]	0.3	0.3
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[1]	(16.3)	(20.9)
Debt Securities, Available-for-sale	[1]	1,240.7	1,300
Fair Value, Recurring | Short-term Investments [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	598	709.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[1]	0.3	0.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[1]	(7.7)	(10.8)
Debt Securities, Available-for-sale	[1]	590.6	699.3
Fair Value, Recurring | Short-term Investments [Member] | Municipal obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	14.1	23.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[1]	0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[1]	(0.2)	(0.3)
Debt Securities, Available-for-sale	[1]	13.9	23.1
Fair Value, Recurring | Short-term Investments [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	287.1	233.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[1]	0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[1]	(3.4)	(3.2)
Debt Securities, Available-for-sale	[1]	283.7	230.7
Fair Value, Recurring | Short-term Investments [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	10.2	13.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[1]	0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[1]	(0.2)	(0.3)
Debt Securities, Available-for-sale	[1]	10	13.5
Fair Value, Recurring | Short-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	347.3	339.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[1]	0	0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[1]	(4.8)	(6.3)
Debt Securities, Available-for-sale	[1]	$ 342.5	$ 333.4
[1]Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.

Fair Value Measurements - Amort

Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details) $ in Millions	Sep. 30, 2023 USD ($)	[1]
Fair Value Disclosures [Abstract]
Mature in less than one year	$ 473.6
Mature in one to five years	636.7
Mature in more than five years	146.4
Total Amortized Cost	1,256.7
Mature in less than one year	469.5
Mature in one to five years	627.8
Mature in more than five years	143.4
Estimated Fair Value	$ 1,240.7
[1]Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.

Fair Value Measurements (Deta_5

Fair Value Measurements (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest Receivable, Current	$ 11.2	$ 11.6
Ordinary voting shares [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment ownership percentage	38%
Investment Owned, Balance, Shares	12,987,900
Preference shares [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment ownership percentage	28%
Investment Owned, Balance, Shares	9,588,908

Goodwill and Other Purchased _3

Goodwill and Other Purchased Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Goodwill [Line Items]
Goodwill	$ 742,200	$ 741,700
Accumulated impairment loss	(335,200)	(335,200)
Goodwill, net	406,953	406,488
Goodwill, Acquired During Period	400
Goodwill, Foreign Currency Translation Gain (Loss)	100
Goodwill, Period Increase (Decrease)	500
Clinical Diagnostics
Goodwill [Line Items]
Goodwill	408,900	408,400
Accumulated impairment loss	(293,400)	(293,400)
Goodwill, net	115,500	115,000
Goodwill, Acquired During Period	400
Goodwill, Foreign Currency Translation Gain (Loss)	100
Goodwill, Period Increase (Decrease)	500
Life Science
Goodwill [Line Items]
Goodwill	333,300	333,300
Accumulated impairment loss	(41,800)	(41,800)
Goodwill, net	291,500	$ 291,500
Goodwill, Acquired During Period	0
Goodwill, Foreign Currency Translation Gain (Loss)	0
Goodwill, Period Increase (Decrease)	$ 0

Goodwill and Other Purchased _4

Goodwill and Other Purchased Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Acquired Finite-Lived Intangible Assets [Line Items]
Goodwill, Acquired During Period			$ 400
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 556,200		556,200		$ 553,500
Accumulated Amortization	(428,500)		(428,500)		(412,400)
Net Carrying Amount	127,700		127,700		141,100
Amortization [Abstract]
Amortization expense	6,200	$ 6,200	18,100	$ 18,800
Purchased intangibles, net	314,187		314,187		332,147
Intangible Assets, Gross (Excluding Goodwill)	$ 742,700		$ 742,700		$ 744,500
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	5 years 2 months 12 days		5 years 2 months 12 days		5 years
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 104,300		$ 104,300		$ 104,700
Accumulated Amortization	(93,600)		(93,600)		(89,900)
Net Carrying Amount	$ 10,700		$ 10,700		$ 14,800
Know How [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	2 years		2 years		2 years 9 months 18 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 165,100		$ 165,100		$ 166,200
Accumulated Amortization	(156,200)		(156,200)		(153,900)
Net Carrying Amount	$ 8,900		$ 8,900		$ 12,300
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	12 years 2 months 12 days		12 years 2 months 12 days		12 years 9 months 18 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 215,500		$ 215,500		$ 211,100
Accumulated Amortization	(128,400)		(128,400)		(121,600)
Net Carrying Amount	$ 87,100		$ 87,100		$ 89,500
Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	5 years 1 month 6 days		5 years 1 month 6 days		5 years 9 months 18 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 58,800		$ 58,800		$ 59,000
Accumulated Amortization	(41,100)		(41,100)		(38,500)
Net Carrying Amount	$ 17,700		$ 17,700		$ 20,500
Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	5 years 9 months 18 days		5 years 9 months 18 days		6 years 7 months 6 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 6,000		$ 6,000		$ 6,100
Accumulated Amortization	(4,500)		(4,500)		(4,500)
Net Carrying Amount	$ 1,500		$ 1,500		$ 1,600
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	2 years 6 months		2 years 6 months		3 years 1 month 6 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 6,500		$ 6,500		$ 6,400
Accumulated Amortization	(4,700)		(4,700)		(4,000)
Net Carrying Amount	1,800		1,800		2,400
In Process Research and Development [Member]
Amortization [Abstract]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 186,500		$ 186,500		$ 191,000

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 230,400	$ 228,800
Work in process	244,500	220,900
Finished goods	300,900	269,600
Inventory	$ 775,818	$ 719,316

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Supplemental Cash Flow Elements [Abstract]
Net loss	$ 106,257	$ (1,162,251)	$ 68,962	$ (162,808)	$ (925,114)	$ (3,367,347)	$ (987,032)	$ (4,455,269)
Depreciation and amortization							108,700	101,800
Reduction in the carrying amount of right-of-use assets							30,700	29,800
Share-based Compensation							45,100	42,800
(Gains) losses from change in fair market value of equity securities and loan receivable							1,576,500	6,172,300
Gain on Disposition of a division							0	(1,400)
Changes in fair value of contingent consideration							(18,500)	0
Payments of operating lease liabilities							(30,400)	(28,100)
Decrease in accounts receivable							31,600	(44,500)
Decrease (increase) in inventories							(61,700)	(150,600)
Increase in other current assets							15,000	(11,900)
Decrease in accounts payable and other current liabilities							(72,400)	(69,700)
Increase in income taxes payable							56,400	(39,200)
Increase in deferred income taxes							(397,400)	(1,439,100)
Increase in other long term liabilities							3,900	(2,000)
Other							(6,600)	9,900
Net cash provided by operating activities							293,896	114,790
Noncash or Part Noncash Acquisition, Fixed Assets Acquired							2,900	3,300
Noncash or Part Noncash Acquisition, Investments Acquired							$ 0	$ 11,800

Long-Term Debt (Details)

Long-Term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Other Long-term Debt, Current	$ 500	$ 500
Long-term debt, net of current maturities	1,198,713	1,197,716
Finance Lease Obligations | Finance Leases and Other Debt
Debt Instrument [Line Items]
Other Long-term Debt	10,200	10,600
Senior Notes | Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	(11,000)	(12,400)
Long-term debt	1,189,000	1,187,600
Senior Notes | 3.3%, Senior Notes due 2027
Debt Instrument [Line Items]
Senior Notes, Noncurrent	$ 400,000	400,000
Debt Instrument, Interest Rate, Stated Percentage	3.30%
Senior Notes | 3.7%, Senior Notes due 2032
Debt Instrument [Line Items]
Senior Notes, Noncurrent	$ 800,000	$ 800,000
Debt Instrument, Interest Rate, Stated Percentage	3.70%

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			$ (466,822)
Total other comprehensive income (loss) net of tax	$ (124,699)	$ (311,828)	(30,739)	$ (669,661)
Ending balance, Accumulated other comprehensive income	(497,561)		(497,561)
Other (income) expense, net	(20,446)	(3,062)	(87,365)	(42,369)
Accumulated Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			(466,500)	(170,500)
Other Comprehensive Income (Loss), before Reclassifications, before Tax			(34,400)	(654,400)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			0	0
Other Comprehensive Income (Loss), Tax			100	1,100
Total other comprehensive income (loss) net of tax			(34,300)	(653,300)
Ending balance, Accumulated other comprehensive income	(500,800)	(823,800)	(500,800)	(823,800)
Accumulated Defined Benefit Plans Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			10,000	(10,900)
Other Comprehensive Income (Loss), before Reclassifications, before Tax			300	1,400
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			400	(200)
Other Comprehensive Income (Loss), Tax			0	(500)
Total other comprehensive income (loss) net of tax			(100)	1,100
Ending balance, Accumulated other comprehensive income	9,900	(9,800)	9,900	(9,800)
Accumulated Defined Benefit Plans Adjustment | Reclassification Out Of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other (income) expense, net	200	(100)	400	(200)
Accumulated Net Unrealized Investment Gain (Loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			(10,300)	5,800
Other Comprehensive Income (Loss), before Reclassifications, before Tax			3,700	(23,300)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			(1,100)	(600)
Other Comprehensive Income (Loss), Tax			(1,100)	5,300
Total other comprehensive income (loss) net of tax			3,700	(17,400)
Ending balance, Accumulated other comprehensive income	(6,600)	(11,600)	(6,600)	(11,600)
Accumulated Net Unrealized Investment Gain (Loss) | Reclassification Out Of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other (income) expense, net	100	200	1,100	600
AOCI Attributable to Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			(466,800)	(175,600)
Other Comprehensive Income (Loss), before Reclassifications, before Tax			(30,400)	(676,300)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			(700)	(800)
Other Comprehensive Income (Loss), Tax			(1,000)	5,900
Total other comprehensive income (loss) net of tax			(30,700)	(669,600)
Ending balance, Accumulated other comprehensive income	$ (497,500)	$ (845,200)	$ (497,500)	$ (845,200)

Earnings (Loss) Per Share (Deta

Earnings (Loss) Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Basic weighted average shares outstanding	29,102	29,733	29,349	29,819
Effect of potentially dilutive stock options and restricted stock awards	121	0	0	0
Diluted weighted average common shares	29,223	29,733	29,349	29,819
Anti-dilutive shares	154	541	229	541

Other Income, Net (Details)

Other Income, Net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Interest and investment income	$ (17,300)	$ (8,000)	$ (84,100)	$ (45,700)
Net realized (gain) loss on investments	(100)	(200)	(1,600)	600
Financing Receivable, Allowance for Credit Loss, Current	0	5,100		5,100
Increase (Decrease) in Deposit Assets	0	0	0	(1,400)
Escrow Deposit Disbursements Related to Property Acquisition	(2,500)	0	(2,500)	0
Other Nonoperating (Income)	(700)		(2,400)
Other Nonoperating Expense		(400)		(1,000)
Other (income) expense, net	$ (20,446)	$ (3,062)	$ (87,365)	$ (42,369)

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Effective tax rate	22.50%	21.50%	22.80%	23.10%
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	$ 18.8		$ 18.8
Unrecognized Tax Benefits	$ 92		92		$ 85.5
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount			$ 15.2

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Net sales	$ 632,124	$ 680,800	$ 1,990,078	$ 2,071,961
Life Science
Segment Reporting Information [Line Items]
Net sales	263,500	317,900	887,300	987,500
Income before income taxes	13,000	51,400	76,700	197,600
Clinical Diagnostics
Segment Reporting Information [Line Items]
Net sales	368,100	361,900	1,100,300	1,081,400
Income before income taxes	78,000	43,900	166,100	167,800
Other Segments
Segment Reporting Information [Line Items]
Net sales	500	1,000	2,500	3,100
Income before income taxes	$ (100)	$ (700)	$ (300)	$ (1,500)

Segment Information (Details)_2

Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Interest expense	$ 12,398	$ 11,663	$ 37,078	$ 26,431
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	137,102	(207,318)	(1,278,496)	(5,795,555)
Marketable Securities, Unrealized Gain (Loss)	36,425	(288,999)	(1,576,542)	(6,172,306)
Net sales	632,124	680,800	1,990,078	2,071,961
Life Science
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	13,000	51,400	76,700	197,600
Net sales	263,500	317,900	887,300	987,500
Other Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(100)	(700)	(300)	(1,500)
Net sales	500	1,000	2,500	3,100
Clinical Diagnostics
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	78,000	43,900	166,100	167,800
Net sales	368,100	361,900	1,100,300	1,081,400
Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	90,900	94,600	242,500	363,900
Segment Reconciling Items
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Marketable Securities, Unrealized Gain (Loss)	36,400	(289,000)	(1,576,500)	(6,172,300)
Foreign Currency Gain (Loss) | Segment Reconciling Items
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	1,700	(4,400)	5,300	(3,100)
Other Nonoperating Income (Expense) | Segment Reconciling Items
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	20,400	3,100	87,400	42,400
Interest Expense | Segment Reconciling Items
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Interest expense	$ (12,300)	$ (11,600)	$ (37,200)	$ (26,500)

Segment Information (Details)_3

Segment Information (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 11,895,943	$ 13,501,666

Restructuring Costs (Details)

Restructuring Costs (Details) - USD ($) $ in Millions	3 Months Ended	4 Months Ended	8 Months Ended	9 Months Ended	32 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 29.5	$ 29.5	$ 29.5	$ 29.5	$ 29.5
Accounts Payable and Accrued Liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	29	29	29	29	29
Other Noncurrent Liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0.5	0.5	0.5	0.5	0.5
Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	1.3			16.6
Cost of Sales
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0.2			3.9
Research and Development Expense
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0			5.3
European Reorganization
Restructuring Cost and Reserve [Line Items]
Restructuring Charges					70
Restructuring Reserve	14.8	14.8	14.8	14.8	14.8	$ 31.6
Restructuring Reserve, Accrual Adjustment				1.4
Payments for Restructuring				(18.1)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss				(0.1)
European Reorganization | Life Science
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0.3	0.3	0.3	0.3	0.3	1.9
Restructuring Reserve, Accrual Adjustment				0
Payments for Restructuring				(1.6)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss				0
European Reorganization | Clinical Diagnostics
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	14.5	14.5	14.5	14.5	14.5	29.7
Restructuring Reserve, Accrual Adjustment				1.4
Payments for Restructuring				(16.5)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss				(0.1)
European and American Reorganization
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		9	15.4	15.4
Restructuring Reserve	10.4	10.4	10.4	10.4	10.4	0
Payments for Restructuring				(5.2)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss				(0.2)
European and American Reorganization | Life Science
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				3.3
Restructuring Reserve	2	2	2	2	2	0
Payments for Restructuring				(1.4)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss				(0.1)
European and American Reorganization | Clinical Diagnostics
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				12.1
Restructuring Reserve	8.4	8.4	8.4	8.4	8.4	0
Payments for Restructuring				(3.8)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss				(0.1)
Additional European and American Reorganization
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				9
Restructuring Reserve	4.3	4.3	4.3	4.3	4.3	0
Payments for Restructuring				(4.7)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss				0
Additional European and American Reorganization | Life Science
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				4.3
Restructuring Reserve	1.4	1.4	1.4	1.4	1.4	0
Payments for Restructuring				(2.9)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss				0
Additional European and American Reorganization | Clinical Diagnostics
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				4.7
Restructuring Reserve	$ 2.9	$ 2.9	$ 2.9	2.9	$ 2.9	$ 0
Payments for Restructuring				(1.8)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss				$ 0

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Operating Lease, Cost	$ 15,700	$ 14,200	$ 47,200	$ 43,200
Finance Lease, Right-of-Use Asset, Amortization	100	100	300	300
Finance Lease, Interest Expense	200	200	600	600
Finance Lease Cost	300	300	900	900
Operating Lease, Payments	10,600	9,500	30,400	28,100
Finance Lease, Interest Payment on Liability	200	200	600	600
Finance Lease, Principal Payments	100	100	300	300
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	36,700	$ 2,300	49,000	$ 9,400
Operating lease right-of-use assets	200,013		200,013		$ 180,952
Current operating lease liabilities	$ 39,116		$ 39,116		$ 36,336
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities		Other current liabilities		Other current liabilities
Operating lease liabilities	$ 167,179		$ 167,179		$ 153,597
Operating Lease, Liability	206,300		206,300		189,900
Finance Lease, Right-Of-Use Asset, before Accumulated Amortization	11,800		11,800		11,900
Finance Lease, Right-Of-Use Asset, Accumulated Amortization	5,700		5,700		5,500
Finance Lease, Right-Of-Use Asset, after Accumulated Amortization	6,100		6,100		6,400
Finance Lease, Liability, Current	500		500		500
Finance Lease, Liability, Noncurrent	9,700		9,700		10,100
Finance Lease, Liability	$ 10,200		$ 10,200		$ 10,600
Operating Lease, Weighted Average Remaining Lease Term	7 years		7 years		7 years
Finance Lease, Weighted Average Remaining Lease Term	14 years		14 years		15 years
Operating Lease, Weighted Average Discount Rate, Percent	3.80%		3.80%		3%
Finance Lease, Weighted Average Discount Rate, Percent	6.40%		6.40%		6.30%
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 10,400		$ 10,400
Finance Lease, Liability, Payments, Remainder of Fiscal Year	300		300
Lessee, Operating Lease, Liability, to be Paid, Year One	45,500		45,500
Finance Lease, Liability, to be Paid, Year One	1,200		1,200
Lessee, Operating Lease, Liability, Payments, Due Year Two	42,600		42,600
Finance Lease, Liability, Payments, Due Year Two	1,100		1,100
Lessee, Operating Lease, Liability, Payments, Due Year Three	31,200		31,200
Finance Lease, Liability, Payments, Due Year Three	1,100		1,100
Lessee, Operating Lease, Liability, Payments, Due Year Four	24,700		24,700
Finance Lease, Liability, Payments, Due Year Four	1,100		1,100
Lessee, Operating Lease, Liability, Payments, Due after Year Five	82,700		82,700
Finance Lease, Liability, Payments, Due after Year Five	11,900		11,900
Lessee, Operating Lease, Liability, Payments, Due	237,100		237,100
Finance Lease, Liability, Payment, Due	16,700		16,700
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(30,800)		(30,800)
Finance Lease, Liability, Undiscounted Excess Amount	$ (6,500)		$ (6,500)
Minimum
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term			1 year
Maximum
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term			16 years